Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (NCT06145308) | Clinical Trial Compass
RecruitingPhase 2
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
China39 participantsStarted 2023-08-15
Plain-language summary
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.
Who can participate
Age range
18 Years – 100 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with histopathologic diagnosis of salivary gland carcinoma
* The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining.
* ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;
* Age 18 or older - no upper limit;
* Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures;
⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions:
⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation/operation;
⑩Ability to comply with research visit schedules and other programmatic requirements.
Exclusion Criteria:
* Known hypersensitivity or delayed anaphylaxis to any agents in this trial;
* Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover;
* Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ;
* To study the occurrence of arterial/venous thrombosis events within 6 months before medication;
* Major cardiovascular diseases;
* Is suffering from uncontrolled sy…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
ORR
Timeframe: ORR at the end of Cycle 2 (each cycle is 21 days)